DYOR. Analysis is highly-speculative. The analysis assumes RACE are successful in their strategy to prove up value of Zantrene in terms of clinical safety and efficacy for a range of cancer, camcer/cardio-protection and cardio-renal targets and then successfully achieve a commercial transaction. Potential outcomes include buyout, partnership or independent commercialisation.
Further to this, US-listed early-stage precision oncology companies are trading an a median market cap of USD $1.03B ( AUD $1.44B ) or around $8 per share fully-diluted.
RAC is significantly undervalued.
Here's a summary of my analysis with value indicators plotted on a chart - buyouts, partnerships, early-stage peers.
RAC is in a long-term uptrend. At the moment we have consolidation underway. I think this will eventually breakout (could take 4-5 months) for significant upside once the big seller runs out of stock.
- Forums
- ASX - By Stock
- Ann: Expanded Heart Protection Discovery for Zantrene
DYOR. Analysis is highly-speculative. The analysis assumes RACE...
- There are more pages in this discussion • 325 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.61 |
Change
-0.045(2.73%) |
Mkt cap ! $272.2M |
Open | High | Low | Value | Volume |
$1.65 | $1.67 | $1.51 | $214.0K | 133.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 708 | $1.60 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.65 | 500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 708 | 1.600 |
1 | 1916 | 1.560 |
3 | 10751 | 1.550 |
2 | 2929 | 1.520 |
1 | 3000 | 1.500 |
Price($) | Vol. | No. |
---|---|---|
1.645 | 500 | 1 |
1.650 | 7000 | 2 |
1.690 | 3300 | 1 |
1.700 | 8424 | 6 |
1.740 | 4163 | 3 |
Last trade - 15.50pm 04/06/2024 (20 minute delay) ? |
|
|||||
Last
$1.60 |
  |
Change
-0.045 ( 2.74 %) |
|||
Open | High | Low | Volume | ||
$1.66 | $1.68 | $1.52 | 19707 | ||
Last updated 15.48pm 04/06/2024 ? |
Featured News
RAC (ASX) Chart |